TP53 and lung adenocarcinoma: In EGFR-mutated lung adenocarcinoma models with TKI resistance, Dio transcriptionally inhibits the expression of tyrosine phosphatase SHP2 through reactive oxygen species (ROS)-dependent activation of p53.